



# **HIV-Eradication - should we be optimistic ?**



**Pietro Vernazza  
Fachbereich Infektiologie / Spitalhygiene  
Kantonsspital St. Gallen**

# Eradication ?




# Success of HAART

## Hopes in 1996




But....

# Not as simple as that




The next problem to solve

# Long lived Memory T-Cells



## The end of the dream

# Slow decay of latently infected pool



Here we show that even in treated patients who have had no detectable viremia for as long as 7 years, the reservoir decays so slowly ( $t_{1/2} = 44$  months) that eradication is unlikely.

# Latently infected resting T cells



---

- **Permit long term persistence**
- **HIV replication following Tx cessation**
- **Resistant to HAART**
- **Major obstacle to eradication**

Provirus:

# Let's get rid of the problem

Eradicate Provirus vs. Silencing Provirus





# Strategies to attack latency

---

- **Activating latently infected cells + HAART**
  - Cytokines, LPS, Superantigens
  - Il-2 (Kulkosky, 2003)
  - Il-2 +OKT3 (Stelbrink 2002)
- **Cytotoxic targetting of latent cells**
  - Requires specific target on infected cells
  - Other infected cells or compartments might limit approach

Too toxic,  
non specific

Activating NFκB

## **Prostratin – Homalanthus nutans**


---

- **(deoxy-)Phorbol Ester (PHA)**
- **Protein kinase C activator**
- **Does not induce tumor formation**
- **Activates NF-κB**
- **Activates transcription of HIV**



Ok, replicating HIV is no problem, but..


# What Determines Latency ?



Griffiths et al, 2004


Accessing the target

# Chromatin remodelling




## Valproate

# No Stimulation of HIV infection




# Proof of concept study

## Study Design



## Pilot study


# Decay of latently infected cells $\uparrow\uparrow$






# Specific Fusion Between CCR5-conjugated proteo-liposomes & gp160-expressing Cells

---



**Liposomes fused with BHK gp160-expressing cells.**

Bronshtein, IAS 2006, Toronto LB304



**CCR5-conjugated proteo-liposomal cores localization inside BHK gp160-expressing cells.**




New technologies

# Proteo-liposomes to target cell

## Long term goal

To develop CCR5 conjugated proteo-liposomal constructs for targeted drug delivery & inactivation of free virions



# Future steps

---

- **Improve targeting systems**
- **Simplify methods to count latently infected cells**
- **Define mechanism of nuclear retention**
- **Understand silencing**

## Eradication

# Should we be optimistic?

- **Of course, we should!**
- **We can handle replicating virus**
- **Let's understand latency**
- **Kick the dormant HIV out of the cell**
- **Design target systems**
- **Don't forget silencing !**